ATE402191T1 - Rekombinante il-18 antikörper und deren verwendung - Google Patents

Rekombinante il-18 antikörper und deren verwendung

Info

Publication number
ATE402191T1
ATE402191T1 AT00918152T AT00918152T ATE402191T1 AT E402191 T1 ATE402191 T1 AT E402191T1 AT 00918152 T AT00918152 T AT 00918152T AT 00918152 T AT00918152 T AT 00918152T AT E402191 T1 ATE402191 T1 AT E402191T1
Authority
AT
Austria
Prior art keywords
recombinant
antibodies
Prior art date
Application number
AT00918152T
Other languages
English (en)
Inventor
Yen Ho
Stephen D Holmes
Alexander Taylor
Sherin ABDEL-MEGUID
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE402191T1 publication Critical patent/ATE402191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00918152T 1999-03-19 2000-03-17 Rekombinante il-18 antikörper und deren verwendung ATE402191T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12529999P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
ATE402191T1 true ATE402191T1 (de) 2008-08-15

Family

ID=22419067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918152T ATE402191T1 (de) 1999-03-19 2000-03-17 Rekombinante il-18 antikörper und deren verwendung

Country Status (28)

Country Link
US (2) US6706487B1 (de)
EP (2) EP1163271B1 (de)
JP (1) JP2002542769A (de)
KR (1) KR100697120B1 (de)
CN (1) CN1246335C (de)
AR (1) AR022952A1 (de)
AT (1) ATE402191T1 (de)
AU (1) AU764622B2 (de)
BR (1) BR0008688A (de)
CA (1) CA2368965C (de)
CO (1) CO5470287A1 (de)
CY (1) CY1108387T1 (de)
CZ (1) CZ303704B6 (de)
DE (1) DE60039589D1 (de)
DK (1) DK1163271T3 (de)
ES (1) ES2308974T3 (de)
HK (1) HK1043798B (de)
HU (1) HU228931B1 (de)
IL (1) IL144995A0 (de)
MY (1) MY124219A (de)
NO (1) NO330391B1 (de)
NZ (1) NZ513699A (de)
PL (1) PL202396B1 (de)
PT (1) PT1163271E (de)
SI (1) SI1163271T1 (de)
TR (3) TR200202253T2 (de)
WO (1) WO2000056771A1 (de)
ZA (1) ZA200107639B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852266A (en) * 1993-07-14 1998-12-22 Hitachi, Ltd. Vacuum circuit breaker as well as vacuum valve and electric contact used in same
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
JP4992068B2 (ja) * 2000-01-27 2012-08-08 メディミューン，エルエルシー 超高親和性中和抗体
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
ME00546B (me) * 2000-02-21 2011-10-10 Serono Lab Korišćenje inhibitora il-18
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
AU2004235595C1 (en) 2003-04-30 2009-09-24 Japan Science And Technology Agency Human antihuman interleukin-18 antibody, fragment thereof and method of using the same
AU2011224023C1 (en) * 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
EP2532677A1 (de) 2005-10-21 2012-12-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
GB0610438D0 (en) * 2006-05-25 2006-07-05 Glaxo Group Ltd Immunoglobulins
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
EP2210901A4 (de) * 2007-10-19 2012-04-25 Immunas Pharma Inc Zur spezifischen bindung an ein oligomer fähiger antikörper, und dessen verwendung
DK2246427T3 (da) * 2008-02-08 2017-02-20 Immunas Pharma Inc Antistoffer der er i stand til at binde specifikt til amyloid-beta oligomerer og anvendelse deraf
EP2281004A4 (de) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc Prostataspezifische membranantigenantikörper und antigenbindende fragmente
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
EP2326315A1 (de) * 2008-08-18 2011-06-01 Glaxo Group Limited Behandlung einer autoimmunkrankheit mit il-18-antagonisten
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
EP2419447B1 (de) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
EP2377583A1 (de) * 2009-06-30 2011-10-19 Gosen Co., Ltd. Schlägersaite, herstellungsverfahren dafür und damit bespannter schläger
US8613924B2 (en) 2009-08-06 2013-12-24 Immunas Pharma, Inc. Antibodies that specifically bind to A beta oligomers and use thereof
JP5769316B2 (ja) 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
SG182783A1 (en) * 2010-02-09 2012-09-27 Glaxo Group Ltd Treatment of a metabolic disorder
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
RU2605928C2 (ru) * 2010-03-02 2016-12-27 Эббви Инк. Терапевтические dll4-связывающие белки
WO2011150086A2 (en) * 2010-05-25 2011-12-01 The Regents Of The University Of Colorado, A Body Corporate Diagnosis and treatment of autoimmune disease
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
CA2822515C (en) 2010-12-20 2023-04-25 Medimmune Limited Anti-il-18 antibodies and their uses
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
ES2742413T3 (es) 2012-11-21 2020-02-14 Km Biologics Co Ltd Nuevo anticuerpo humano contra IL-18
KR102511343B1 (ko) * 2015-03-05 2023-03-17 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체
JP2023530489A (ja) * 2020-06-18 2023-07-18 ネクストキュア インコーポレイテッド Ｆｌｒｔ３媒介性シグナル伝達を調節するための組成物及び方法
JPWO2023286694A1 (de) 2021-07-13 2023-01-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr) 1997-09-01 2000-05-05 Boots Co Plc Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Also Published As

Publication number Publication date
PL350460A1 (en) 2002-12-16
DE60039589D1 (de) 2008-09-04
NZ513699A (en) 2004-02-27
DK1163271T3 (da) 2008-11-10
HUP0200502A3 (en) 2003-12-29
PL202396B1 (pl) 2009-06-30
IL144995A0 (en) 2002-06-30
CA2368965C (en) 2010-05-18
CN1246335C (zh) 2006-03-22
TR200102733T2 (tr) 2002-04-22
US20040141964A1 (en) 2004-07-22
CY1108387T1 (el) 2014-02-12
JP2002542769A (ja) 2002-12-17
HK1043798B (zh) 2009-04-09
AR022952A1 (es) 2002-09-04
EP1163271A4 (de) 2003-04-09
HK1043798A1 (en) 2002-09-27
CN1352650A (zh) 2002-06-05
US6706487B1 (en) 2004-03-16
SI1163271T1 (sl) 2008-10-31
PT1163271E (pt) 2008-09-16
NO330391B1 (no) 2011-04-04
HUP0200502A2 (en) 2002-06-29
TR200202253T2 (tr) 2002-12-23
EP1163271A1 (de) 2001-12-19
NO20014524D0 (no) 2001-09-18
ZA200107639B (en) 2002-09-17
MY124219A (en) 2006-06-30
EP1163271B1 (de) 2008-07-23
EP1961768A1 (de) 2008-08-27
AU3901600A (en) 2000-10-09
KR100697120B1 (ko) 2007-03-20
WO2000056771A1 (en) 2000-09-28
CA2368965A1 (en) 2000-09-28
NO20014524L (no) 2001-11-14
ES2308974T3 (es) 2008-12-16
AU764622B2 (en) 2003-08-28
CO5470287A1 (es) 2004-12-30
BR0008688A (pt) 2002-01-08
HU228931B1 (en) 2013-06-28
CZ20013362A3 (cs) 2002-03-13
KR20020008130A (ko) 2002-01-29
CZ303704B6 (cs) 2013-03-27
TR200202254T2 (tr) 2002-12-23

Similar Documents

Publication Publication Date Title
DE60039589D1 (de) Rekombinante il-18 antikörper und deren verwendung
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
DE60105859D1 (de) Urazil Verbindungen und deren Verwendung
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE59802439D1 (de) Spiroverbindungen und deren verwendung
CY2012002I2 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DE59803292D1 (de) Triazolverbindungen und deren verwendung als dopamin-d 3-liganden
DE60229509D1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE69817432D1 (de) Cycloolefinpolymere und deren Verwendung
DE60027927D1 (de) Harzstruktur und ihre verwendung
DE60230245D1 (de) Wabenkonstruktion und deren zusammenbau
DE60216345D1 (de) Gummimischung und deren Verwendung
DE69729449D1 (de) Rekombinante alpha-2,3-sialyltransferasen und deren verwendung
DE60021507D1 (de) Uracilverbindungen und deren Verwendung
ATE355377T1 (de) Hybridprotease mit verringerter antigenizität und deren verwendung
ATE353367T1 (de) Group b streptococcus proteine und deren verwendung
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE60005514D1 (de) Dormanz-brechende zusammenstezung und deren verwendung
DE60013191D1 (de) Tensidzusammensetzung und deren Verwendung
DE59906951D1 (de) Spiroverbindungen und deren verwendung
DE10049596B4 (de) Dielektrische Keramikzusammensetzung und deren Verwendung
DE50106529D1 (de) Pfropfcopolymermischung mit verbesserten eigenschaften und deren verwendung als haftvermittler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163271

Country of ref document: EP